PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer - Reck, M; Paz-Ares, L G; de Marinis, F (J Thorac Oncol, 2014)
et al.